ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   
 News | News By Subject | News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) (SRPT) to Present Company Overview at the 2012 Rodman & Renshaw Annual Global Investment Conference


8/31/2012 9:59:00 AM

CAMBRIDGE, MA--(Marketwire - August 31, 2012) - Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the 2012 Rodman & Renshaw Annual Global Investment Conference in New York, NY on Monday, September 10, 2012 at 10:25 a.m. Eastern Time. Chris Garabedian, Sarepta's President and CEO, will be the presenter.

The presentation will be webcast live under the events section of Sarepta Therapeutics' website at www.sareptatherapeutics.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics -- formerly AVI BioPharma -- is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sareptatherapeutics.com.


Sarepta Media and Investor Contact:
Erin Cox
425.354.5140
Email Contact


Read at BioSpace.com
 
 Read Article at  Related Companies  News Categories
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES